Neopterin, CD4+CD28− lymphocytes and the extent and severity of coronary artery disease

ObjectivesMacrophages and pro-inflammatory CD3+CD4+CD28− T lymphocytes are involved in atherosclerotic plaque destabilization. Whether neopterin, a macrophage-specific activation-marker, and circulating CD3+CD4+CD28− cells are also related to the severity and extent of coronary artery disease (CAD) in stable patients is still unclear.MethodsCoronary angiograms of 30 patients with stable angina pectoris were graded using the Gensini severity and an extent score. Patients were grouped according to the median of each score. Lymphocyte subsets were determined by FACS analysis and neopterin by radioimmunoassay. Peripheral endothelial function of the brachial artery (FMD) shown to correlate with cardiovascular risk factors was evaluated using high-resolution ultrasound.ResultsMore extensive CAD was associated with increased neopterin levels (8.3 ± 3.3 vs. 5.5 ± 1.2 nmol/L, p < 0.001) and increased CD3+CD4+CD28− cells (3.1 ± 1.6 vs. 2.0 ± 1.2%, p < 0.05). A high Gensini severity score was associated with increased neopterin levels (7.8 ± 2.7 vs. 6.3 ± 1.7 nmol/L, p < 0.05), but not with CD3+CD4+CD28− cells. Neopterin correlated with both the extent (r = 0.59, p < 0.001) and the Gensini score (r = 0.57, p < 0.003). FMD was not correlated with both scores.ConclusionsNeopterin and CD3+CD4+CD28− lymphocytes are associated with CAD extent in stable patients, thereby emphasizing the inherent role of inflammation in atherogenesis itself beyond plaque destabilization. Neopterin's correlation with CAD severity might be additionally useful in identifying patients eligible for revascularization procedures.